Zoladex Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Zoladex Market is Segmented By Dosage (3.6 mg, 10.8 mg), By Application(Prostate Cancer, Breast Cancer, Endometriosis, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2023-2030

Zoladex Market Overview

The global zoladex market reached US$ 0.92 billion in 2022 and is expected to reach US$ 1.03  billion by 2030 growing with a CAGR of 1.4% during the forecast period 2023-2030. The zoladex market trends show rising demand for treatment options for breast or prostate cancer. ​

Furthermore, steady growth, driven by a combination of continuous technological advancements, growing environmental awareness, and the rising need for streamlined operations will drive the zoladex market size. The market is experiencing a growth demand for products from North American areas as a result of the rising advancements in this field with significant competitors like AstraZeneca, Mithra Pharmaceuticals, Alvogen Inc. actively operating in the market.

Zoladex Market Scope

To Know More Download Sample

Zoladex Market Dynamics

Increasing Prevalence of Breast Cancer Associated with Infertility due to Chemotherapy Drive the Growth of the Zoladex Market

The rising cases of breast cancer related to infertility caused owing to chemotherapy along with several research studies are driving the zoladex market’s growth. Based on the stage of the tumour, chemotherapy is a common form of treatment for breast cancer patients. Chemotherapy increases the risk of infertility. In addition, the age of the patient as well as the kinds and dosages of the chemotherapy drugs the patient is taking affect fertility following chemotherapy. 

The best probability of getting pregnant following chemotherapy is for cancer patients under the age of 30. In general, a woman's chances of having viable eggs following chemotherapy increase with age. Additionally, some chemotherapy drugs, such as Cytoxan (cyclophosphamide), are more likely than others to result in infertility. According to a study, premenopausal women with early-stage, hormone-receptor-negative breast cancer who received Zoladex treatment along with chemotherapy before having their cancer surgically removed had a significantly lower risk of becoming infertile later on.

Rising Advancements or Research and Development by Key Players Creates Opportunities for the Growth of the Market

Goserelin acetate is the active ingredient in the experimental novel medication LY01005, which is designed for intramuscular injection as extended-release microspheres. Pharmacodynamics, pharmacokinetics, and toxicology tests on rats were carried out to support the suggested clinical trials or marketing application of LY01005. In the pharmacological investigation in rats, LY01005 first increased testosterone levels above physiological levels at 24 hours after administration, but these levels thereafter quickly decreased to castration levels. 

LY01005's potency was comparable to that of the Zoladex comparison, but it had a more enduring and steady impact. Nearly all of the positive results of LY01005 in the toxicity study on rats, including changes in hormones (FSH, LH, testosterone, and progestin) and reproductive system (vagina, ovary, uterus, cervix uteri, testis, mammary gland, prostate and epididymis), were linked to the pharmacological effects of goserelin. These research and advancements will lead to growth of more treatment options for breast or prostate cancer.

Side Effects of the Zoladex Implant will hamper the growth of the market

Several side effects are associated with the Zoladex injection. It is possible to experience hot flashes (flushing), headaches, dizziness, increased perspiration, decreased sexual interest or ability, difficulties sleeping, nausea, a change in breast size, dryness in the vagina, or hair loss. There may also be pain, bleeding, bruising, redness, or inflammation where the injection was given. Rarely, this medicine may induce a spike in blood sugar, which can lead to or exacerbate diabetes.

Zoladex Market Segment Analysis

The global zoladex market is segmented based on dosage, application, distribution channel and region.

Owing to High Utilization, the 3.6 mg from Dosage Segment Accounted for Approximately 55.6% of the Zoladex Market Share

The 3.6 mg category held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in breast cancer incidence worldwide, amongst the population. The 3.6 mg implant is used for endometriosis that has been visually proven, to reduce symptoms and the amount of endometrial lesions, for uterine fibroids, to shrink lesions while decreasing symptoms, for advanced breast cancer treatment in premenopausal women and for adjuvant treatment of early-stage breast cancer, in which hormonal manipulation is appropriate. 

Every 28 days, one implant must be subcutaneously inserted into the front abdominal wall in men with prostate cancer. A delayed injection may result in an increase in testosterone levels. In case of females, one implant ought to be injected subcutaneously onto the anterior abdomen wall every 28 days, and treatment should last for two to five years when zoladex is employed as a substitute to combination chemotherapy in early breast cancer.

Source: DataM Intelligence Analysis (2023)

Zoladex Market Geographical Penetration

North America Accounted for Approximately 40.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for zoladex for treatment purpose in healthcare, manufacturers in North America have chances of increasing their operations. There are several producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for zoladex treatment. Increasing expenditure on healthcare and rising utilization among end users for cancer treatment, advancement of technologies for administration via different routes, and increase in pharmaceutical business establishment across the region are also contributing to the growth of zoladex market share of this region. 

It is also anticipated that the main healthcare organizations' and enterprises' strategic initiatives or research projects along with innovative product development, which constantly seeks to enhance the available medications alternatives, will contribute to the expanding demand. The above-mentioned factors further proves the dominance of North America on a global scale.

Source: DataM Intelligence Analysis (2023)

Zoladex Market Major Key Players

The major global players in the zoladex market include Tersera Therapeutics, Mithra Pharmaceuticals, Alvogen, AMW GmbH, AstraZeneca, Luye Pharma, Atossa Therapeutics, Sanofi, Fosun Pharma and Bachem among others.

COVID-19 Impact Analysis On Zoladex Market

Russia-Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide zoladex market. The growth of the global zoladex market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Dosage

• 3.6 mg 
• 10.8 mg

By Application

• Prostate Cancer 
• Breast Cancer
• Endometriosis
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 30, 2021, a long-term investment fund with a pharmaceuticals concentration is Aztiq Pharma Partners whose goal is to make it easier for patients to acquire high-quality, cheap medications  announced that it was successful in raising $100 million in financing to buy freshly issued shares of Alvogen US. Aztiq used the funds to purchase a 17% share in Alvogen US at a pre-money valuation of US$350 million from Fora.
• On June 24, 2021, the firm Mithra, which focuses on women's health, is happy to report that it was able to successfully renegotiate the earnouts associated with two of the medicines in its Complex Therapeutic product portfolio including the Myring hormonal contraceptive ring and the Zoreline implant. A biodegradable implant called Zoreline administered subcutaneously is used to treat breast cancer, prostate cancer, and benign gynecological conditions such endometriosis and uterine fibroids. 
• On July, 29, 2022, in a study done on premenopausal individuals who tested positive for ER, the European Society for Medical Oncology reported that 2 years of adjuvant endocrine therapy had a 20-year benefit. Premenopausal individuals with oestrogen receptor (ER)-positive breast cancer in the Stockholm portion of the Zoladex in Premenopausal individuals study (STO-5) show a substantial 20-year advantage after 2 years of tamoxifen, goserelin, and the combination, relative to no adjuvant endocrine treatment. Additionally, the study contends that goserelin benefits genomic high-risk patients early while tamoxifen benefits genomic low-risk patients significantly over the long term.

Why Purchase the Report?

• To visualize the global zoladex market segmentation based on dosage, application, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of zoladex market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global zoladex market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies